Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.9000 (3.51%) ($5.6400 - $5.9200) on Thu. Jan. 16, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.53% (three month average) | RSI | 80 | Latest Price | $5.9000(3.51%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1.3% a day on average for past five trading days. | Weekly Trend | ADMS advances 19.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TLT(13%) BNDX(10%) VCSH(7%) BWX(5%) VCIT(4%) | Factors Impacting ADMS price | ADMS will decline at least -3.765% in a week (0% probabilities). XHB(-25%) XLE(-20%) URA(-20%) XRT(-19%) USO(-18%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.765% (StdDev 7.53%) | Hourly BBV | 0 () | Intraday Trend | 2.8% | | | |
|
5 Day Moving Average | $5.55(6.31%) | 10 Day Moving Average | $5.12(15.23%) | 20 Day Moving Average | $4.48(31.7%) | To recent high | -19.2% | To recent low | 15.5% | Market Cap | $167m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |